Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

RM, Rich; PJ, Rosenfeld; CA, Puliafito; SR, Dubovy; JL, Davis; HW Jr, Flynn; S, Gonzalez; WJ, Feuer; RC, Lin; GA, Lalwani; JK, Nguyen; G, Kumar

doi:10.1097/01.iae.0000225766.75009.3a

Public

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Shared by NobleBlocks on May 1, 2006 • 12:00 AM UTC

Authors:

Rich RM

Rosenfeld PJ

Puliafito CA

Abstract

<h4>Purpose</h4>To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD).<h4>Methods</h4>A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal b...

Discussions